...
首页> 外文期刊>Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus >Circulating miRNAs as novel potential biomarkers for esophageal squamous cell carcinoma diagnosis: a meta-analysis update
【24h】

Circulating miRNAs as novel potential biomarkers for esophageal squamous cell carcinoma diagnosis: a meta-analysis update

机译:作为食管鳞状细胞癌诊断的新型潜在生物标志物循环miRNA:META分析更新

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Early detection of esophageal squamous cell carcinoma (ESCC) is urgently needed to reduce the high morbidity and mortality of disease. Circulating microRNAs (miRNAs) are promising molecular biomarkers for ESCC prediction. We performed a comprehensive meta-analysis to systematically evaluate the diagnostic accuracy of circulating miRNAs in diagnosis of ESCC patients. Eligible studies were identified and assessed for quality employing multiple search strategies. Summary estimates for sensitivity, specificity, and other measures of accuracy of miRNAs in the diagnosis of ESCC were pooled using the bivariate random effects model. Atotal of 27 studies from 11 published articles were included in the meta-analysis. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating miRNAs for the diagnosis of ESCC were 79.9% (95% confidence intervals [CI]: 76.2%-83.1%), 81.3% (95% CI: 75.7-85.9), 4.27 (95% CI: 3.27-5.58), 0.25 (95% CI: 0.21-0.29), and 17.29 (95% CI: 12.01-24.86), respectively. The area under the summary receiver operating characteristic curve was 0.87 (95% CI: 0.84-0.90). The subgroup analyses based on research country (China vs. Japan), specimen type (plasma vs. serum), miRNAs profiling (single vs. multiple), and test method (screening vs. candidate; Taqman vs. SYBR) indicated no significant difference in the diagnostic accuracy of each subgroup. Collectively, our findings indicate that circulating miRNAs have significant potential to be used as noninvasive biomarkers for early detection of ESCC. Moreover, the subgroup analyses demonstrated the feasibility of using blood miRNAs as an ESCC diagnostic biomarker in Japanese and Chinese populations. Further, both plasma and serum are recommended as clinical specimens for miRNA detection. Further studies will be needed to validate these findings using larger numbers of patients.
机译:迫切需要早期检测食道鳞状细胞癌(ESCC),以降低疾病的高发病率和死亡率。循环的MicroRNA(miRNA)是ESCC预测的主要分子生物标志物。我们进行了全面的荟萃分析,以系统地评估循环miRNA在ESCC患者诊断中的诊断准确性。鉴定和评估符合条件的研究,以获得多种搜索策略的质量。使用双变量随机效应模型汇集了敏感性,特异性和MiRNA精度准确度措施的概述估计。从11个公布的文章中的27项研究的地点包含在Meta分析中。循环miRNA的整体敏感性,特异性,正似然比,负似然比和循环ESCC诊断的诊断比率为79.9%(95%置信区间[CI]:76.2%-83.1%),81.3%(95%) CI:75.7-85.9),4.27(95%CI:3.27-5.58),0.25(95%CI:0.21-0.29),分别为17.29(95%CI:12.01-24.86)。在操作特征曲线下的摘要接收器下的区域为0.87(95%CI:0.84-0.90)。基于研究国家(中国与日本),标本型(血浆与血清),miRNA分析(单vs.多个)和测试方法(筛选与候选人;塔克曼与Sybr)的亚组分析(筛查与候选人)表示没有显着差异在每个子组的诊断准确性。集体,我们的研究结果表明,循环miRNA具有显着用作非侵入性生物标志物,以便早期检测ESCC。此外,亚组分析证明了使用血液miRNA作为日语和中国人群的ESCC诊断生物标志物的可行性。此外,推荐血浆和血清作为miRNA检测的临床标本。需要进一步的研究来使用较大数量的患者验证这些发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号